Entering text into the input field will update the search result below

Intrommune advancing peanut allergy candidate, pre-IND meeting with FDA completed

Sep. 06, 2018 11:15 AM ETAnaptysBio, Inc. (ANAB) StockBy: Douglas W. House, SA News Editor4 Comments
  • Privately held Intromune Therapeutics met recently with the FDA to discuss the details of an IND for INT301, an immunotherapy to treat peanut allergy. Once approved, clinical studies may begin.
  • INT301 is based on the company's OMIT (oral mucosal immunotherapy) platform which enables the administration of the drug via a specialized toothpaste.
  • Peanut allergy-related tickers: (NASDAQ:ANAB -1.3%)(AIMT +0.3%)(DBVT -0.8%)

Recommended For You

About ANAB Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
ANAB--
AnaptysBio, Inc.